Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes

References

• TianJGuXSunYEffect of statin therapy on the progression of coronary atherosclerosisBMC Cardiovasc Disord2012127022938176
   PubMed Web of Science ®Google Scholar
• AlpertJSA few unpleasant facts about atherosclerotic arterial disease in the United States and the worldAm J Med2012125983984022938924
   PubMed Web of Science ®Google Scholar
• Global Atlas on Cardiovascular Disease Prevention and ControlGeneva, SwitzerlandWorld Health Organization2011 Available from: http://www.who.int/cardiovascular_diseases/publications/atlas_cvd/en/Accessed June 20, 2013
   Google Scholar
• FusterVKellyBBCommittee on Preventing the Global Epidemic of Cardiovascular Disease: Meeting the Challenges in Developing CountriesPromoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health Institute of Medicine Board on Global HealthWashington, DCThe National Academies Press2010
   Google Scholar
• MyerburgRJJunttilaMJSudden cardiac death caused by coronary heart diseaseCirculation201212581043105222371442
   PubMed Web of Science ®Google Scholar
• Di AngelantonioESarwarNPerryPEmerging risk factors collaboration. Major lipids, apolipoproteins, and risk of vascular diseaseJAMA2009302181993200019903920
   PubMed Web of Science ®Google Scholar
• SmithGDEbrahimSMendelian randomization: prospects, potentials, and limitationsInt J Epidemiol2004331304215075143
   PubMed Web of Science ®Google Scholar
• TothPPPotterDMingEEPrevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003–2006J Clin Lipidol20126432533022836069
   PubMed Web of Science ®Google Scholar
• CarrollMDKitBKLacherDASheroSTMussolinoMETrends in lipids and lipoproteins in US adults, 1988–2010JAMA2012308151545155423073951
   PubMed Web of Science ®Google Scholar
• VesperHWKuiperHCMirelLBJohnsonCLPirkleJLLevels of plasma trans-fatty acids in non-Hispanic white adults in the United States in 2000 and 2009JAMA2012307656256322318273
   PubMed Web of Science ®Google Scholar
• [No authors listed]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet19943448934138313897968073
   PubMed Web of Science ®Google Scholar
• SacksFMPfefferMAMoyeLACholesterol and Recurrent Events Trial InvestigatorsThe effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levelsN Engl J Med199633514100110098801446
   PubMed Web of Science ®Google Scholar
• ShepherdJCobbeSMFordIPrevention of coronary heart disease with pravastatin in men with hypercholesterolemiaN Engl J Med199533320130113077566020
   PubMed Web of Science ®Google Scholar
• DownsJRClearfieldMWeisSPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention StudyJAMA199827920161516229613910
   PubMed Web of Science ®Google Scholar
• [No authors listed]The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levelsN Engl J Med199833919134913579841303
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet2002360932672212114036
   PubMed Web of Science ®Google Scholar
• RahmanMBaimbridgeCDavisBRALLHAT Officers and Coordinators for the ALLHAT Collaborative Research GroupThe Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)JAMA2002288282998300712479764
   PubMedGoogle Scholar
• ShepherdJBlauwGJMurphyMBPravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialLancet200236093461623163012457784
   PubMed Web of Science ®Google Scholar
• SeverPSSDahlöfBPoulterNPrevention of coronary and stroke events with atorvastatin in hypertensivepatients who have average or lower than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet200336193641149115812686036
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter, randomised placebo-controlled trialLancet2004364943568569615325833
   PubMed Web of Science ®Google Scholar
• KnoppRHD’EmdenMSmildeJGPocockSJEfficacy and safety of atorvastatin in the prevention of cardiovascular endpoints insubjects with type 2 diabetes. The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)Diabetes Care20062971478148516801565
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonEFonsecaFAHRosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinN Engl J Med2008359212195220718997196
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation2002106253143342112485966
   PubMed Web of Science ®Google Scholar
• SmithSCJrAllenJBlairSNAHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood InstituteCirculation2006113192363237216702489
   PubMed Web of Science ®Google Scholar
• GrahamIAtarDBorch-JohnsenKEuropean guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)Eur Heart J200714Suppl 2E1E40
   Google Scholar
• BuseJBGinsbergHNBakrisGLPrimary prevention of cardiovascular diseases in people with diabetes mellitus. A Scientific Statement from the American Heart Association and the American Diabetes AssociationCirculation2007115111412617192512
   PubMed Web of Science ®Google Scholar
• RydénLStandlEBartnikMGuidelines on diabetes, pre-diabetes, and cardiovascular diseaseEur Heart J20079Suppl CC3C74
   Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2008Diabetes Care200831Suppl 1S12S5418165335
   PubMed Web of Science ®Google Scholar
• NissenSETuzcuEMSchoenhagenPEffect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis a randomized controlled trialJAMA200429191071108014996776
   PubMed Web of Science ®Google Scholar
• CannonCPBraunwaldEMcCabeCHIntensive and moderate lipid lowering with statins after acute coronary syndromesN Engl J Med2004350151495150415007110
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med2005352141425143515755765
   PubMed Web of Science ®Google Scholar
• BaigentCKeechAKearneyPMEfficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536694931267127816214597
   PubMed Web of Science ®Google Scholar
• KearneyPMBlackwellPMCollinsREfficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a metaanalysisLancet2008371960711712518191683
   PubMed Web of Science ®Google Scholar
• ZellwegerMJKaiserCJegerRCoronary artery disease progression late after successful stent implantationJ Am Coll Cardiol201259979379922361397
   PubMed Web of Science ®Google Scholar
• ColomboALatibADisease progression is as important as culprit lesion treatmentJ Am Coll Cardiol201259980080122361398
   PubMed Web of Science ®Google Scholar
• BhattDLEagleKOhmanEMComparative determinants of four-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosisJAMA2010304121350135720805624
   PubMed Web of Science ®Google Scholar
• StegPGBhattDLWilsonPWFOne-year cardiovascular event rates in outpatients with atherothrombosisJAMA2007297111197120617374814
   PubMed Web of Science ®Google Scholar
• BayturanOKapadiaSNichollsSJClinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterolJ Am Coll Cardiol201055242736274220538166
   PubMed Web of Science ®Google Scholar
• LibbyPThe forgotten majority. Unfinished business in cardiovascular risk reductionJ Am Coll Cardiol20054671225122816198835
   PubMed Web of Science ®Google Scholar
• O’KeefeJHJrCordainLHarrisWHMoeRMVogelROptimal low-density lipoprotein is 50 to 70 mg/dL: lower is better and physiologically normalJ Am Coll Cardiol200442112142214615172426
   PubMedGoogle Scholar
• MenottiAKeysAKromhoutDBlackburnHInter-cohort differences in coronary heart disease mortality in the 25-year follow-up of the Seven Countries StudyEur J Epidemiol1993955275268307138
   PubMed Web of Science ®Google Scholar
• SteinbergDWitztumJLInhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levelsProc Natl Acad Sci U S A2009106249546954719506257
   PubMed Web of Science ®Google Scholar
• MayerGPoirierSSeidahNGAnnexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levelsJ Biol Chem200828346317913180118799458
   PubMed Web of Science ®Google Scholar
• LibbyPInflammation in atherosclerosisArterioscler Thromb Vasc Biol20123292045205122895665
   PubMed Web of Science ®Google Scholar
• QuillardTLibbyPMolecular imaging of atherosclerosis for improving diagnostic and therapeutic developmentCirc Res2012111223124422773426
   PubMed Web of Science ®Google Scholar
• WangJCBennettMAging and atherosclerosis. Mechanisms, functional consequences, and potential therapeutics for cellular senescenceCirc Res2012111224525922773427
   PubMed Web of Science ®Google Scholar
• LibbyPFat fuels the flame: triglyceride-rich lipoproteins and arterial inflammationCirc Res2007100329930117307968
   PubMed Web of Science ®Google Scholar
• DuewellPKonoHRaynerKJNLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystalsNature201046472931357136120428172
   PubMed Web of Science ®Google Scholar
• ThornalleyPJRabbaniNMethylgloxal modification of LDL: proatherogenicity without oxidation opens new paths to prevent cardiovascular diseaseClin Lipidol201166631634
   Web of Science ®Google Scholar
• VirellaGLopes-VirellaMFThe pathogenic role of the adaptive immune response to modified LDL in diabetesFront Endocrinol (Lausanne)201237622715334
   PubMedGoogle Scholar
• CroceKLibbyPIntertwining of thrombosis and inflammation in atherosclerosisCurr Opin Hematol2007141556117133101
   PubMed Web of Science ®Google Scholar
• BorissoffJISpronkHMHten CateHThe hemostatic system as a modulator of atherosclerosisN Engl J Med2011364181746176021542745
   PubMed Web of Science ®Google Scholar
• BoumanACSmitsJJTen CateHTen Cate-HoekAJMarkers of coagulation, fibrinolysis and inflammation in relation to the post thrombotic syndromeJ Thromb Haemost20121081532153822642402
   PubMed Web of Science ®Google Scholar
• SalomonRNHughesCCSchoenFJPayneDDPoberJSLibbyPHuman coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cellsAm J Pathol1991138407917982012171
   PubMedGoogle Scholar
• NaganoHMitchellRNTaylorMKHasegawaSTilneyNLLibbyPInterferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse heartsJ Clin Invest199710035505559239401
   PubMed Web of Science ®Google Scholar
• LeyKMillerYIHedrickCCMonocyte and macrophage dynamics during atherogenesisArterioscler Thromb Vasc Biol20113171506151621677293
   PubMed Web of Science ®Google Scholar
• FuYMooreXLLeeMKSCaveolin-1 plays a critical role in the differentiation of monocytes into macrophagesArterioscler Thromb Vasc Biol2012329e117e12522772753
   PubMed Web of Science ®Google Scholar
• JohnstoneSRKronckeBMStraubACMAPK phosphorylation of connexin 43 promotes binding of cyclin E and smooth muscle cell proliferationCirc Res2012111220121122652908
   PubMed Web of Science ®Google Scholar
• LiaoXSluimerJCWangYMacrophage autophagy plays a protective role in advanced atherosclerosisCell Metab201215454556322445600
   PubMed Web of Science ®Google Scholar
• NavebMAnanthramaiahGMReddySTThe oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDLJ Lipid Res2004456993100715060092
   PubMed Web of Science ®Google Scholar
• LibbyPRidkerPMHanssonGKInflammation in atherosclerosis. From pathophysiology to practiceJ Am Coll Cardiol200954232129213819942084
   PubMed Web of Science ®Google Scholar
• MillerYIChoiSHWiesnerPOxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunityCirc Res2011108223524821252151
   PubMed Web of Science ®Google Scholar
• MooreKJTabasIMacrophages in the pathogenesis of atherosclerosisCell2011145334155521529710
   PubMed Web of Science ®Google Scholar
• LudewigBLamanJDThe in and out of monocytes in atherosclerotic plaques: balancing inflammation through migrationProc Natl Acad Sci U S A200410132115291153015292506
   PubMed Web of Science ®Google Scholar
• FeigJEParathathSRongJXReversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaquesCirculation2011123998999821339485
   PubMed Web of Science ®Google Scholar
• van GilsJMDerbyMCFernandesLRThe neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaquesNat Immunol201213213614322231519
   PubMed Web of Science ®Google Scholar
• MooreKJFisherEAMacrophages, atherosclerosis and the potential of netrin-1 as a novel target for future therapeutic interventionFuture Cardiol20128334935222642628
   PubMedGoogle Scholar
• SarwarNButterworthASFreitagDFInterleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studiesLancet201237998221205121322421339
   PubMed Web of Science ®Google Scholar
• The Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) ConsortiumThe interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysisLancet201237998221214122422421340
   PubMed Web of Science ®Google Scholar
• GengYJLibbyPEvidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1β-converting enzymeAm J Pathol199514722512667639325
   PubMed Web of Science ®Google Scholar
• GaleaJArmstrongJGadsdonPHoldenHFrancisSEHoltCMInterleukin-1β in coronary arteries of patients with ischemic heart diseaseArterioscler Throm Vasc Biol199616810001016
   PubMed Web of Science ®Google Scholar
• RidkerPMThurenTZalewskiAInterleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)Am Heart J2011162459760521982649
   PubMed Web of Science ®Google Scholar
• RidkerPMHowardCPWalterVEffects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized placebo controlled trialCirculation2012126232739274823129601
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govThe Cardiovascular Inflammation Reduction Trial Available from: http://clinicaltrials.gov/show/NCT01594333Accessed June 20, 2013
   Google Scholar
• RidkerPMTesting the inflammatory hypothesis of atherothrombosis: scientific rationale for the Cardiovascular Inflammation Reduction Trial (CIRT)J Thromb Haemost20097S133233919630828
   PubMedGoogle Scholar
• National Institutes of HealthNIH launches trial to evaluate anti-inflammatory treatment for preventing heart attacks, strokes, and cardiovascular deaths8222012 Available from: http://www.nhlbi.nih.gov/news/press-releases/2012/nih-launches-trial-to-evaluate-anti-inflammatory-treatment-for-preventing-heart-attacks-strokes-and-cardiovascular-deaths.htmlAccessed June 20, 2013
   Google Scholar
• SantovitoDMezzettiACipolloneFMicroRNAs and atherosclerosis: new actors for an old movieNutr Metab Cardiovasc Dis2012221193794322748605
   PubMed Web of Science ®Google Scholar
• ChenLJLimSHYehYTLienSCChiuJJRoles of microRNAs in atherosclerosis and restenosisJ Biomed Sci20121917922931291
   PubMedGoogle Scholar
• ObergHHJurickeMKabelitzDWeschDRegulation of T cell activation by TLR ligandsEur J Cell Biol2011906–758259221292344
   PubMed Web of Science ®Google Scholar
• HouBReizisBDeFrancoALToll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanismsImmunity200829227228218656388
   PubMed Web of Science ®Google Scholar
• PackardRLichtmanALibbyPInnate and adaptive immunity in atherosclerosisSemin Immunopathol200931152219449008
   PubMed Web of Science ®Google Scholar
• MantheyHDZerneckeADendritic cells in atherosclerosis: functions in immune regulation and beyondThromb Haemost2011106577277821901235
   PubMed Web of Science ®Google Scholar
• DöringYMantheyHDrechslerMAuto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosisCirculation2012125131673168322388324
   PubMed Web of Science ®Google Scholar
• HuangCCLiuKPopeRMActivated TLR signaling in atherosclerosis among women with lower Framingham risk score: the Multi-Ethnic Study Of AtherosclerosisPLoS ONE201166e2106721698167
   PubMed Web of Science ®Google Scholar
• Dd WigrenMBjörkbackaHAnderssonLLow levels of circulating CD4þFoxP3þ T cells are associated with an increased risk for development of myocardial infarction but not for strokeArterioscler Thromb Vasc Biol20123282000200422628434
   PubMed Web of Science ®Google Scholar
• KlingenbergRLebensMHermanssonAIntranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosisArterioscler Thromb Vasc Biol201030594695220167655
   PubMed Web of Science ®Google Scholar
• HermanssonAJohanssonDKKetelhuthDFJAnderssonJZhouXHanssonGKImmunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic miceCirculation2011123101083109121357823
   PubMed Web of Science ®Google Scholar
• SubramanianMThorpEHanssonGKTabasITreg-mediated suppression of atherosclerosis requires MYD88 signaling in DCsJ Clin Invest2013123117918823257360
   PubMed Web of Science ®Google Scholar
• Ait-OufellaHSalomonBLPotteauxSNatural regulatory T cells control the development of atherosclerosis in miceNat Med200612217818016462800
   PubMed Web of Science ®Google Scholar
• KlingenbergRGerdesNBadeauRBImpairment of FOXP3+ regulatory T cells mediated promotes hypercholesterolemia and atherosclerosisJ Clin Invest201312331323133423426179
   PubMed Web of Science ®Google Scholar
• ChengXYuXDingYJThe Th17/Treg imbalance in patients with acute coronary syndromeClin Immunol20081271899718294918
   PubMed Web of Science ®Google Scholar
• ZhouLChongMMLittmanDRPlasticity of CD4þ T cell lineage differentiationImmunity2009305646e5519464987
   PubMed Web of Science ®Google Scholar
• JørgensenTCapewellSPrescottEPopulation-level changes to promote cardiovascular healthEur J Prev Cardiol201320340942122514213
   PubMed Web of Science ®Google Scholar
• BjörkbackaHFredriksonGNNilssonJEmerging biomarkers and intervention targets for immune-modulation of atherosclerosis – a review of the experimental evidenceAtherosclerosis2013227191723177975
   PubMed Web of Science ®Google Scholar
• CreaFLiuzzoGPathogenesis of acute coronary syndromesJ Am Coll Cardiol201361111123158526
   PubMed Web of Science ®Google Scholar
• BelkinaACNikolajczykBSDenisGVBET Protein function is required for inflammation: brd2 genetic disruption and bet inhibitor jq1 impair mouse macrophage inflammatory responsesJ Immunol201319073670367823420887
   PubMed Web of Science ®Google Scholar
• AulchenkoYSRipattiSLindqvistILoci influencing lipid levels and coronary heart disease risk in 16 European population cohortsNat Genet2009411475519060911
   PubMed Web of Science ®Google Scholar
• KaleaAZHarrisonSCStephensJWTalmudPJGenetic susceptibility for coronary heart disease and type 2 diabetes complicationsClin Chem201258581882022361938
   PubMed Web of Science ®Google Scholar
• SchunkertHKonigIRKathiresanSLarge-scale association analysis identifies 13 new susceptibility loci for coronary artery diseaseNat Genet201143433333821378990
   PubMed Web of Science ®Google Scholar
• GottesmanODrillELotayVBottingerEPeterICan genetic pleiotropy replicate common clinical constellations of cardiovascular disease and risk?PLoS One201279e4641923029515
   PubMed Web of Science ®Google Scholar
• RobertsRStewartAFRGenetics of coronary artery disease in the 21st centuryClin Cardiol201235953654022588700
   PubMed Web of Science ®Google Scholar
• AndersonJLHorneBDThe 9p21 locus and coronary heart disease: initiator, promoter, or precipitator?J Am Coll Cardiol201056648748920670759
   PubMed Web of Science ®Google Scholar
• MuhlesteinJBAndersonJLThe 9p21.3 genetic region and coronary heart disease: where do we go from here?J Am Coll Cardiol201158443543721757123
   PubMed Web of Science ®Google Scholar
• SuperkoHRMomaryKMLiYStatins personalizedMed Clin N Am201296112313922391257
   PubMed Web of Science ®Google Scholar
• ThompsonADi AngelantonioESarwarNAssociation of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary riskJAMA2008299232777278818560005
   PubMed Web of Science ®Google Scholar
• TeslovichTMMusunuruKSmithAVBiological, clinical and population relevance of 95 loci for blood lipidsNature2010466730770771320686565
   PubMed Web of Science ®Google Scholar
• KellerMPAttieADPhysiological insights gained from gene expression analysis in obesity and diabetesAnnu Rev Nutr20103034136420415584
   PubMed Web of Science ®Google Scholar
• O’ConnorDRaoFNaqshbandiDAutonomic and hemodynamic origins of pre-hypertension: central role of heredityJ Am Coll Cardiol201259242206221622676942
   PubMed Web of Science ®Google Scholar
• GreenDJJonesHThijssenDCableNTAtkinsonGFlow-mediated dilation and cardiovascular event prediction: does nitric oxide matter?Hypertension201157336336921263128
   PubMed Web of Science ®Google Scholar
• AndersonTJCharbonneauFTitleLMMicrovascular function predicts cardiovascular events in primary prevention: long-term results from the Firefighters and Their Endothelium (FATE) studyCirculation2011123216316921200002
   PubMed Web of Science ®Google Scholar
• YeboahJCrouseJRHsuFCBurkeGLHerringtonDMBrachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health StudyCirculation2007115182390239717452608
   PubMed Web of Science ®Google Scholar
• RauscherFMGoldschmidt-ClermontPJDavisBHAging, progenitor cell exhaustion, and atherosclerosisCirculation2003108445746312860902
   PubMed Web of Science ®Google Scholar
• WassmannSWernerNCzechTNickenigGImprovement of endothelial function by systemic transfusion of vascular progenitor cellsCirc Res2006998e74e8316990568
   PubMed Web of Science ®Google Scholar
• WernerNKosiolSSchieglTCirculation endothelial progenitor cells and cardiovascular outcomesN Engl J Med200535310999100716148285
   PubMed Web of Science ®Google Scholar
• FadiniGPLosordoDDimmelerSCritical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic useCirc Res2012110462463722343557
   PubMed Web of Science ®Google Scholar
• VasaMFichtlschererSAdlerCIncrease in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery diseaseCirculation200110322885289011413075
   PubMedGoogle Scholar
• Van CraenenbroeckEMConraadsVMEndothelial progenitor cells in vascular health: focus on lifestyleMicrovasc Res201079318419220053364
   PubMed Web of Science ®Google Scholar
• Müller-EhmsenJBraunDSchneiderTDecreased number of circulating progenitor cells in obesity: beneficial effects of weight reductionEur Heart J200829121560156818515295
   PubMed Web of Science ®Google Scholar
• FadiniGPIs bone marrow another target of diabetic complications?Eur J Clin Invest201141445746321175550
   PubMed Web of Science ®Google Scholar
• RautouPEVionACAmabileNMicroparticles, vascular function, and atherothrombosisCirc Res2011109559360621852557
   PubMed Web of Science ®Google Scholar
• BurgerDKwartDGMontezanoACMicroparticles induce cell cycle arrest through redox-sensitive processes in endothelial cells: implications in vascular senescenceJ Am Heart Assoc201213e00184223130145
   PubMed Web of Science ®Google Scholar
• JungCSörenssonPSalehNArhedenHRydénLPernowJCirculating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with ST-elevation myocardial infarctionAtherosclerosis2012221122623122245039
   PubMed Web of Science ®Google Scholar
• DevarajSKumaresanPRJialalIC-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunctionClin Chem20111221757176121980169
   PubMedGoogle Scholar
• LiuMLScaliaRMehtaJLWilliamsKJCholesterol-induced membrane microvesicles as novel carriers of damage-associated molecular patterns. Mechanisms of formation, action, and detoxificationArterioscler Thromb Vasc Biol20123293221132121
   Web of Science ®Google Scholar
• HornPCortese-KrottMMAmabileNCirculating microparticles carry a functional endothelial nitric oxide synthase that is decreased in patients with endothelial dysfunctionJ Am Heart Assoc201321e00376423525410
   PubMed Web of Science ®Google Scholar
• SarwarNDaneshJEiriksdottirGTriglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studiesCirculation2007115445045817190864
   PubMed Web of Science ®Google Scholar
• MillerMCannonCPMurphySAImpact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE-IT TIMI 22 trialJ Am Coll Cardiol200851772473018279736
   PubMed Web of Science ®Google Scholar
• BarterPGottoAMLaRosaJCHDL cholesterol, very low levels of LDL cholesterol, and cardiovascular eventsN Engl J Med20073571313021310
   Web of Science ®Google Scholar
• CareyVJBishopLLaranjoNHarshfieldBJKwiatCSacksFMContribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol controlAm J Cardiol2010106675776320816113
   PubMed Web of Science ®Google Scholar
• NichollsSJTuzcuESipahiIStatins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosisJAMA2007297549950817284700
   PubMed Web of Science ®Google Scholar
• PekkanenJLinnSHeissGTen-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular diseaseN Engl J Med1990322170017072342536
   PubMed Web of Science ®Google Scholar
• KonesRPrimary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive surveyDrug Des Devel Ther20115325380
   PubMed Web of Science ®Google Scholar
• KheraAVCuchelMde la Llera-MoyaMCholesterol efflux capacity, high-density lipoprotein function, and atherosclerosisN Engl J Med2011364212713521226578
   PubMed Web of Science ®Google Scholar
• RosensonRSBrewerHBJrDavidsonWSCholesterol efflux and atheroprotection. Advancing the concept of reverse cholesterol transportCirculation2012125151905191922508840
   PubMed Web of Science ®Google Scholar
• HaghpassandMBourassaPAKFranconeOLAielloRJMonocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levelsJ Clin Invest200110891315132011696576
   PubMed Web of Science ®Google Scholar
• TallARWangNMucksavagePIs it time to modify the reverse cholesterol transport model?J Clin Invest200110891273127511696569
   PubMed Web of Science ®Google Scholar
• FengYLievensJJacobsFHepatocyte-specific ABCA1 transfer increases HDL cholesterol but impairs HDL function and accelerates atherosclerosisCardiovasc Res201088237638520562425
   PubMed Web of Science ®Google Scholar
• HaaseCLTybjarg-HansenAGrandePFrikke-SchmidtRGenetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart diseaseJ Clin Endocrinol Metab20109512E500E51020826588
   PubMed Web of Science ®Google Scholar
• HeineckeJWThe protein cargo of HDL: implications for vascular wall biology and therapeuticsJ Clin Lipidol20104537137520975842
   PubMed Web of Science ®Google Scholar
• NavabMReddySTVan LentenBJFogelmanAMHDL and cardiovascular disease: atherogenic and atheroprotective mechanismsNat Rev Cardiol20118422223221304474
   PubMed Web of Science ®Google Scholar
• SchwartzGGOlssonAGAbtMEffects of dalcetrapib in patients with a recent acute coronary syndromeN Engl J Med2012367222089209923126252
   PubMed Web of Science ®Google Scholar
• ZhangQYinHLiuPZhangHSheMEssential role of HDL on endothelial progenitor cell proliferation with PI3K/Akt/cyclin D1 as the signal pathwayExp Biol Med2010235910821092
   Web of Science ®Google Scholar
• AviramMRosenblatMParaoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis developmentFree Radic Biol Med20043791304131615454271
   PubMed Web of Science ®Google Scholar
• YuhannaISZhuYCoxBEHigh-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthaseNat Med20017785385711433352
   PubMed Web of Science ®Google Scholar
• AndrewsKLMooreXLChin-DustingJPAnti-atherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endotheliumClin Exp Pharmacol Physiol201037773674220374256
   PubMed Web of Science ®Google Scholar
• ProsserHCNgMKBursillCAThe role of cholesterol efflux in mechanisms of endothelial protection by HDLCurr Opin Lipidol201223318218922488423
   PubMed Web of Science ®Google Scholar
• ChiuveSEMcCulloughMLSacksFMRimmEBHealthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and non users of lipid-lowering and anti-hypertensive medicationsCirculation2006114216016716818808
   PubMed Web of Science ®Google Scholar
• UmaerusMRosengrenBFagerbergBHurt-CamejoECamejoJDL2 interferes with LDL association with arterial proteoglycans: a possible athero-protective effectAtherosclerosis2012125111512022999079
   PubMedGoogle Scholar
• Van LentenBJHamaSYde BeerFCAnti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell coculturesJ Clin Invest1995966275827678675645
   PubMed Web of Science ®Google Scholar
• McGillicuddyFCde la LleraMMHinkleCCInflammation impairs reverse cholesterol transport in vivoCirculation200911981135114519221221
   PubMed Web of Science ®Google Scholar
• NorataGDPirilloAAmmiratiECatapanoALEmerging role of high density lipoproteins as a player in the immune systemAtherosclerosis20122201112121783193
   PubMed Web of Science ®Google Scholar
• HaasMJMooradianADRegulation of high-density lipoprotein by inflammatory cytokines: establishing links between immune dysfunction and cardiovascular diseaseDiabetes Metab Res Rev2010262909920047197
   PubMed Web of Science ®Google Scholar
• AzzamKMFesslerJBCrosstalk between reverse cholesterol transport and innate immunityTrends Endocrinol Metab201223416917822406271
   PubMed Web of Science ®Google Scholar
• BeslerCLüscherTFLandmesserUMolecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular diseaseEMBO Mol Med20124425126822431312
   PubMed Web of Science ®Google Scholar
• BeslerCHeinrichKRohrerLMechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery diseaseJ Clin Invest201112172693270821701070
   PubMed Web of Science ®Google Scholar
• BrewerHBJrThe evolving role of HDL in the treatment of high-risk patients with cardiovascular diseaseJ Clin Endocrinol Metab20119651246125721389140
   PubMed Web of Science ®Google Scholar
• SchmitzGGrandiMThe molecular mechanisms of HDL and associated vesicular trafficking mechanisms to mediate cellular lipid homeostasisArterioscler Thromb Vasc Biol200929111718172219846837
   PubMed Web of Science ®Google Scholar
• WangSHYuanSGPengDQZhaoSPHDL and ApoA-I inhibit antigen presentation-mediated T cell activation by disrupting lipid rafts in antigen presenting cellsAtherosclerosis2012225110511422862966
   PubMed Web of Science ®Google Scholar
• ZelcerNTontonozPLiver X receptors as integrators of metabolic and inflammatory signalingJ Clin Invest2006116360761416511593
   PubMed Web of Science ®Google Scholar
• ImSSOsborneTFLiver X receptors in atherosclerosis and inflammationCirc Res20111088996100121493922
   PubMed Web of Science ®Google Scholar
• NogheroAPerinoASeanoGLiver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2Arterioscler Thromb Vasc Biol20123292280228822723445
   PubMed Web of Science ®Google Scholar
• OlivierMTanckMWOutRHuman ATP-binding cassette G1 controls macrophage lipoprotein lipase bioavailability and promotes foam cell formationArterioscler Thromb Vasc Biol20123292223223122772754
   PubMed Web of Science ®Google Scholar
• ParpalSKarlssonMThornHStralforsPCholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptorsubstrate-1, but not for mitogen-activated protein kinase controlJ Biol Chem2001276139670967811121405
   PubMed Web of Science ®Google Scholar
• HongZStaiculescuMCHampelPLevitanIForgacsGHow cholesterol regulates endothelial biomechanicsFront Physiol2012342623162471
   PubMed Web of Science ®Google Scholar
• PierinLMEddyRJFuortesMSeveauSCasuloMaxfieldFRMembrane lipid organization is critical for human neutrophil polarizationJ Biol Chem200327812108311084112522144
   PubMed Web of Science ®Google Scholar
• BodinSWelchMDPlasma membrane organization is essential for balancing competing pseudopod- and uropod-promoting signals during neutrophil polarization and migrationMol Biol Cell20056125773578316207810
   PubMedGoogle Scholar
• FriszJFLouKKlitzingHADirect chemical evidence for sphingolipid domains in the plasma membranes of fibroblastsProc Natl Acad Sci U S A20131108E613E62223359681
   PubMed Web of Science ®Google Scholar
• FruchartJCAilhaudGApolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significanceClin Chem19923867937971597003
   PubMed Web of Science ®Google Scholar
• MackeyRHGreenlandPGoffDCLloyd-JonesDSibleyCTMoraSHigh-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis)J Am Coll Cardiol201260650851622796256
   PubMed Web of Science ®Google Scholar
• WatanabeJChouKJLiaoJCDifferential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosisJ Biol Chem200728232236982370717556366
   PubMed Web of Science ®Google Scholar
• RiwantoMRohrerLRoschitzkiBAltered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodelingCirculation2013127889190423349247
   PubMed Web of Science ®Google Scholar
• HolzerMBirner-GruenbergerRStojakovicTUremia alters HDL composition and functionJ Am Soc Nephrol20112291631164121804091
   PubMed Web of Science ®Google Scholar
• GinsbergHNBrownWVApolipoprotein CIII: 42 years old and even more interestingArterioscler Thromb Vasc Biol201131347147321325666
   PubMed Web of Science ®Google Scholar
• YaoZHuman apolipoprotein C-III – a new intrahepatic protein factor promoting assembly and secretion of very low density lipoproteinsCardiovasc Hematol Disord Drug Targets201212213314023030451
   PubMedGoogle Scholar
• SacksFMAlaupovicPMoyeLAVLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trialCirculation20001021886189211034934
   PubMed Web of Science ®Google Scholar
• MendivilCORimmEBFurtadoJChiuveSESacksFMLow-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart diseaseCirculation2011124192065207221986282
   PubMed Web of Science ®Google Scholar
• SacksFMZhengCCohnJSComplexities of plasma apolipoprotein C-III metabolismJ Lipid Res20115261067107021421846
   PubMed Web of Science ®Google Scholar
• JensenMKRimmEBFurtadoJDSacksFMApolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart diseaseJ Am Heart Assoc201212e000232
   Web of Science ®Google Scholar
• ZhengCAzcutiaVAikawaEStatins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesionEur Heart J201334861562422927557
   PubMed Web of Science ®Google Scholar
• OoiEMChanDTWattsGFPlasma apolipoprotein C-III metabolism in patients with chronic kidney diseaseJ Lipid Res201152679480021297177
   PubMed Web of Science ®Google Scholar
• FarbsteinDLevyAPHDL dysfunction in diabetes: causes and possible treatmentsExpert Rev Cardiovasc Ther201210335336122390807
   PubMedGoogle Scholar
• BucalaRMakitaZKoschinskiTCeramiAVlassaraHLipid advanced glycosylated pathway for lipid oxidation in vivoProc Natl Acad Sci U S A19939014643464388341651
   PubMed Web of Science ®Google Scholar
• AttmanPOSamuelssonOAlaupovicPLipoprotein metabolism and renal failureAm J Kidney Dis19932165735928503411
   PubMed Web of Science ®Google Scholar
• KeaneWFTomassiniJENeffDRLipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosisJ Atheroscler Thromb201320212313323095239
   PubMed Web of Science ®Google Scholar
• WannerCKraneVMarzWAtorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysisN Engl J Med2005353323824816034009
   PubMed Web of Science ®Google Scholar
• FellstromBCJardineAGSchmiederRERosuvastatin and cardiovascular events in patients undergoing hemodialysisN Engl J Med2009360141395140719332456
   PubMed Web of Science ®Google Scholar
• BaigentCLandrayMJReithCThe effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialLancet201137797842181219221663949
   PubMed Web of Science ®Google Scholar
• ZalewskiAMacpheeCRole of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic targetArterioscler Thromb Vasc Biol200525592393115731492
   PubMed Web of Science ®Google Scholar
• The Lp-PLA2 Studies CollaborationLipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studiesLancet201037597251536154420435228
   PubMed Web of Science ®Google Scholar
• DohiTMiyauchiKOhkawaRHigher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiographyAnn Clin Biochem201249Pt 652753322933444
   PubMedGoogle Scholar
• KizerJRUmansJGZhuJLipoprotein-associated phospholipase A2 mass and activity and risk of cardiovascular disease in a population with high prevalences of obesity and diabetes: the Strong Heart StudyDiabetes Care201235484084722338104
   PubMed Web of Science ®Google Scholar
• RidkerPMacFadyenJGWolfertRLKoenigWRelationship of lipoprotein-associated phospholipase A2 mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trialClin Chem201258587788622419750
   PubMed Web of Science ®Google Scholar
• MallatZLambeauGTedguiALipoprotein-associated and secreted phospholipases A2 in cardiovascular disease: roles as biological effectors and biomarkersCirculation2010122212183220021098459
   PubMed Web of Science ®Google Scholar
• GonçalvesIEdsfeldtAYoungKNEvidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammationArterioscler Thromb Vasc Biol20123261505151222499993
   PubMed Web of Science ®Google Scholar
• YamamotoSYanceyPGIkizlerTDysfunctional high-density lipoprotein in patients on chronic hemodialysisJ Am Coll Cardiol201260232372237923141484
   PubMed Web of Science ®Google Scholar
• SavelJLafitteMPucheuYPradeauVTabarinACouffinhalTVery low levels of HDL cholesterol and atherosclerosis, a variable relationship – a review of LCAT deficiencyVasc Health Risk Manag2012835736122701329
   PubMedGoogle Scholar
• VoightBFPelosoGMOrho-MelanderMPlasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation studyLancet2012380984157258022607825
   PubMed Web of Science ®Google Scholar
• Osei-HwediehDOAmarMSviridovDRemaleyATApolipoprotein mimetic peptides: mechanisms of action as antiatherogenic agentsPharmacol Ther20111301839121172387
   PubMed Web of Science ®Google Scholar
• RaynerKJSheedyFJEsauCCAntagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosisJ Clin Invest201112172921293121646721
   PubMed Web of Science ®Google Scholar
• RaynerKJEsauCCHussainFNInhibition of miR-33a/b in nonhuman primates raises plasma HDL and lowers VLDL triglyceridesNature2011478736940440722012398
   PubMed Web of Science ®Google Scholar
• NichollsSJGordonAJohanssonJEfficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trialJ Am Coll Cardiol20115791111111921255957
   PubMed Web of Science ®Google Scholar
• NissenSETsunodaTTuzcuEMEffect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trialJAMA2003290172292230014600188
   PubMed Web of Science ®Google Scholar
• ShawJABobikAMurphyAInfusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaqueCirc Res2008103101084109118832751
   PubMed Web of Science ®Google Scholar
• WaksmanRTorgusonRKentKMA first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndromeJ Am Coll Cardiol201055242727273520538165
   PubMed Web of Science ®Google Scholar
• HuFBStampferMJHaffnerSMSolomonCGWillettWCMansonJEElevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetesDiabetes Care20022571129113412087009
   PubMed Web of Science ®Google Scholar
• LilliojaSMottDMHowardBVImpaired glucose tolerance as a disorder of insulin actionN Engl J Med198831819121712253283552
   PubMed Web of Science ®Google Scholar
• LilliojaSMottDMSpraulMInsulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima IndiansN Engl J Med199332927198819928247074
   PubMed Web of Science ®Google Scholar
• DeFronzoRABonadonnaRXFerranniniBPathogenesis of NIDDM. A balanced overviewDiabetes Care19921533183681532777
   PubMed Web of Science ®Google Scholar
• Rask-MadsenCKahnCRTissue-specific insulin signaling, metabolic syndrome, and cardiovascular diseaseArterioscler Thromb Vasc Biol20123292052205922895666
   PubMed Web of Science ®Google Scholar
• YuKCCooperADPostprandial lipoproteins and atherosclerosisFront Biosci20016D332D35411229885
   PubMed Web of Science ®Google Scholar
• GiaccoFBrownleeMOxidative stress and diabetic complicationsCirc Res201010791058107021030723
   PubMed Web of Science ®Google Scholar
• GrundySMPre-diabetes, metabolic syndrome, and cardiovascular riskJ Am Coll Cardiol201259763564322322078
   PubMed Web of Science ®Google Scholar
• DadonaPGhanimHGChaudhuriAAn inflammatory tale from 3 fatty depotsJ Am Coll Cardiol201158325625721737015
   PubMed Web of Science ®Google Scholar
• GustafsonBHammarstedtAAnderssonCXSmithUInflamed adipose tissue. A culprit underlying the metabolic syndrome and atherosclerosisArterioscler Thromb Vasc Biol200727112276228317823366
   PubMed Web of Science ®Google Scholar
• TaskinenMRAdielsMWesterbackaJDual metabolic defects are required to produce hypertriglyceridemia in obese subjectsArterioscler Thromb Vasc Biol20113192144215021778423
   PubMed Web of Science ®Google Scholar
• KathiresanSOtvosJDSullivanLMIncreased small low density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart StudyCirculation20061131202916380547
   PubMed Web of Science ®Google Scholar
• GruzdevaOUchasovaEDylevaYBelikEKashtalapVBarbarashORelationship between free fatty acids, insulin resistance markers, and oxidized lipoproteins in myocardial infarction and acute left ventricular failureDiabetes Metab Syndr Obes20136110311123550027
   PubMedGoogle Scholar
• KonesRMetabolism of the acutely ischemic and hypoxic heartCrit Care Med1973163213304272729
   PubMedGoogle Scholar
• TaegtmeyerHMcNultyPYoungMEAdaptation and maladaptation of the heart in diabetes: part I: general conceptsCirculation2002105141727173311940554
   PubMed Web of Science ®Google Scholar
• PrasadABekkerPTsimikasSAdvanced glycation endproducts and diabetic cardiovascular diseaseCardiol Rev201220417718322314141
   PubMed Web of Science ®Google Scholar
• LowHHoangAForbesJAdvanced glycation end-products (AGEs) and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse modelsDiabetologia20125592513252122572804
   PubMed Web of Science ®Google Scholar
• TabasIMacrophage death and defective inflammation resolution in atherosclerosisNat Rev Immunol2010101364619960040
   PubMed Web of Science ®Google Scholar
• BayturanOTuzcuMLavoieAThe metabolic syndrome, its component risk factors, and progression of atherosclerosisArch Intern Med2010170547848420212186
   PubMed Web of Science ®Google Scholar
• KondoTOsugiSShimokataKMetabolic syndrome and all-cause mortality, cardiac events, and cardiovascular events: a follow-up study in 25,471 young- and middle-aged Japanese menEur J Cardiovasc Prev Rehabil201118457458021450628
   PubMedGoogle Scholar
• Posadas-SánchezRPosadas-RomeroCMendoza-PérezECholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dLAm J Cardiol2012109563664122169129
   PubMed Web of Science ®Google Scholar
• RothenbacherDBrennerHMärzWKoenigWAdiponectin, risk of coronary heart disease and correlations with cardiovascular risk markersEur Heart J200526161640164615932907
   PubMed Web of Science ®Google Scholar
• BelalcazarMLangWHaffnerSMAdiponectin and the mediation of HDL cholesterol change with improved lifestyle: the Look AHEAD studyJ Lipid Res201253122726273322956782
   PubMed Web of Science ®Google Scholar
• BełtowskiJJamroz-Wi-niewskaAWidomskaSAdiponectin and its role in cardiovascular diseasesCardiovasc Haematol Disord Drug Targets200881746
   PubMedGoogle Scholar
• RobinsonKPrinsJVenkateshBClinical review: adiponectin biology and its role in inflammation and critical illnessCrit Care201115222121586104
   PubMed Web of Science ®Google Scholar
• GiorginoFLeonardiniALaviolaLCardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trialsAnn N Y Acad Sci201312811365023387439
   PubMedGoogle Scholar
• GaedePVedelPLarsenNMultifactorial intervention and cardiovascular disease in patients with type 2 diabetesN Engl J Med2003348538339312556541
   PubMed Web of Science ®Google Scholar
• GaedePLund-AndersenHParvingHHPedersenOEffect of a multifactorial intervention on mortality in type 2 diabetesN Engl J Med2008358658059118256393
   PubMed Web of Science ®Google Scholar
• BrownleeMThe pathobiology of diabetic complications: a unifying mechanismDiabetes20055461615162515919781
   PubMed Web of Science ®Google Scholar
• TikellisCThomasMCHarcourtMTCardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEsAm J Physiol Endocrinol Metab20082952E323E33018477705
   PubMed Web of Science ®Google Scholar
• DandonaPChaudhuriAMohantyPMacronutrients, advanced glycation end products, and vascular reactivityDiabetes Care200730102750275117901533
   PubMed Web of Science ®Google Scholar
• YanSFRamasamyRNakaYSchmidtAMGlycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyondCirc Res200393121159116914670831
   PubMed Web of Science ®Google Scholar
• MariaZYinWRubensteinDAGlycated albumin and pathological shear stress alters endothelial cell thrombogenic potential, pro-inflammatory state and cytoskeletal dynamicsJ Diabetes Metab2011S4003
   Google Scholar
• TakeuchiMTakinoJYamagishiSInvolvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategyCurr Drug Targets201011111468148220583971
   PubMed Web of Science ®Google Scholar
• YamagishiSINakamuraKMatsuiTUedaSNodaYImaizumiTInhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular diseaseCardiovasc Ther2008261505818466420
   PubMed Web of Science ®Google Scholar
• WinMTTYamamotoYMunesueSRegulation of RAGE for attenuating progression of diabetic vascular complicationsExp Diabetes Res2012201289460522110482
   PubMedGoogle Scholar
• YounisNNDurringtonPNHDL functionality in diabetes mellitus: potential importance of glycationClin Lipidol201275561578
   Web of Science ®Google Scholar
• SoranHDurringtonPNSusceptibility of LDL and its subfractions to glycationCurr Opin Lipidol201122425426121734572
   PubMed Web of Science ®Google Scholar
• YounisNNSoranHSharmaRSmall-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetesDiab Vasc Dis Res20107428929520876207
   PubMed Web of Science ®Google Scholar
• YounisNYSoranHSharmaRCharlton-MenysVDurringtonPNLipoprotein glycation in atherogenesisClin Lipidol200946781790
   Web of Science ®Google Scholar
• VeiraiahAHyperglycemia, lipoprotein glycation, and vascular diseaseAngiology2005564421438
   Web of Science ®Google Scholar
• SrivastavaSKRamanaKVBhatnagarARole of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic optionsEndocr Rev200526338039215814847
   PubMed Web of Science ®Google Scholar
• TangWHMartinKAHwaJAldose reductase, oxidative stress, and diabetic mellitusFront Pharmacol201238722582044
   PubMed Web of Science ®Google Scholar
• ShanmugamNReddyMAGuhaMNatarajanRHigh glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cellsDiabetes20035251256126412716761
   PubMed Web of Science ®Google Scholar
• KingGLDas-EvcimenNRole of protein kinase C in diabetic complicationsExpert Rev Endocrinol Metab2010517788
   PubMedGoogle Scholar
• GeraldesPKingGLActivation of protein kinase C isoforms and its impact on diabetic complicationsCirc Res201010681319133120431074
   PubMed Web of Science ®Google Scholar
• KumashiroNErionDMZhangDCellular mechanism of insulin resistance in nonalcoholic fatty liver diseaseProc Natl Acad Sci U S A201110839163811638521930939
   PubMed Web of Science ®Google Scholar
• SrivastavaAKHigh glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: a potential role in the pathogenesis of vascular dysfunction in diabetesInt J Mol Med200291858911745003
   PubMed Web of Science ®Google Scholar
• SmolockARMishraGEguchiKEguchiSScaliaRProtein kinase C upregulates intercellular adhesion molecule-1 and leukocyte-endothelium interactions in hyperglycemia via activation of endothelial expressed calpainArterioscler Thromb Vasc Biol201131228929621071702
   PubMed Web of Science ®Google Scholar
• AvignonASultanAPKC-B inhibition: a new therapeutic approach for diabetic complications?Diabetes Metab2006323206213
   Web of Science ®Google Scholar
• TuttleKRAndersonPWA novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C β inhibitionAm J Kidney Dis200342345646512955673
   PubMed Web of Science ®Google Scholar
• TaulienCAJoySVRuboxistaurinDrugs Today (Barc)200642957758517028667
   PubMed Web of Science ®Google Scholar
• ShenGXMitochondrial dysfunction, oxidative stress and diabetic cardiovascular disordersCardiovasc Hematol Disord Drug Targets201212210611223030449
   PubMedGoogle Scholar
• GiuglianoDCerielloAPaolissoGOxidative stress and diabetic vascular complicationsDiabetes Care19961932572678742574
   PubMed Web of Science ®Google Scholar
• CerielloANew insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapyDiabetes Care20032651589159612716823
   PubMed Web of Science ®Google Scholar
• GraySPDi MarcoEOkabeJNADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosisCirculation2013127181888190223564668
   PubMed Web of Science ®Google Scholar
• BallingerSWPattersonCYanCNHydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cellsCirc Res200086996096610807868
   PubMed Web of Science ®Google Scholar
• MahEBrunoRSPostprandial hyperglycemia on vascular endothelial function: mechanisms and consequencesNutr Res2012321072774023146769
   PubMed Web of Science ®Google Scholar
• ChengZTsengYWhiteMFInsulin signaling meets mitochondria in metabolismTrends Endocrinol Metab2010211058959820638297
   PubMed Web of Science ®Google Scholar
• DresnerALaurentDMarcucciMEffects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activityJ Clin Invest199910322532599916137
   PubMed Web of Science ®Google Scholar
• PetersenKFShulmanGIPathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitusAm J Cardiol2002905A11G18G
   PubMed Web of Science ®Google Scholar
• LowellBBShulmanGIMitochondrial dysfunction and type 2 diabetesScience2005307570838438615662004
   PubMed Web of Science ®Google Scholar
• KimJAWeiYSowersJRRole of mitochondrial dysfunction in insulin resistanceCirc Res2008102440141418309108
   PubMed Web of Science ®Google Scholar
• MercerJRChengKKFiggNDNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndromeCirc Res201010781021103120705925
   PubMed Web of Science ®Google Scholar
• ShantikumarSCaporaliAEmanueliCRole of microRNAs in diabetes and its cardiovascular complicationsCardiovasc Res201293458359322065734
   PubMed Web of Science ®Google Scholar
• MaZAZhaoZTurkJMitochondrial dysfunction and β-cell failure in type 2 diabetes mellitusExp Diabetes Res2012201270353822110477
   PubMedGoogle Scholar
• HotamisligilGSEndoplasmic reticulum stress and the inflammatory basis of metabolic diseaseCell2010140690091720303879
   PubMed Web of Science ®Google Scholar
• OzcanUYilmazEOzcanLChemical chaperones reduce ER stress and restore glucose homeostasis in mouse model of type II diabetesScience200631357901137114016931765
   PubMed Web of Science ®Google Scholar
• WilliamsRSCanaries in the coal mine: mitochondrial DNA and vascular injury from reactive oxygen speciesCirc Res200086991591610807858
   PubMed Web of Science ®Google Scholar
• DelzenneNMCaniPDGut microbiota and the pathogenesis of insulin resistanceCurr Diab Rep201111315415921431853
   PubMed Web of Science ®Google Scholar
• BurcelinRGaridouLPomieCImmuno-microbiota cross and talk: the new paradigm of metabolic diseasesSemin Immunol2012241677422265028
   PubMed Web of Science ®Google Scholar
• MoreiraAPTexeiraTFFerreiraABPeluzio MdoCAlfenas RdeCInfluence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemiaBr J Nutr2012108880180922717075
   PubMedGoogle Scholar
• DeFronzoRADavidsonJADel PratoSThe role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemiaDiabetes Obes Metab201214151421955459
   PubMed Web of Science ®Google Scholar
• ShiHKokoevaMVInouyeKTzameliIYinHFlierJSTLR4 links innate immunity and fatty acid-induced insulin resistanceJ Clin Invest2006116113015302517053832
   PubMed Web of Science ®Google Scholar
• KimFPhamMLuttrellIToll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesityCirc Res2007100111589159617478729
   PubMed Web of Science ®Google Scholar
• ColeJEGeorgiouEMonacoCThe expression and functions of toll-like receptors in atherosclerosisMediators Inflamm2010201039394620652007
   PubMed Web of Science ®Google Scholar
• van BeekMOravecz-WilsonKIDelektaPCBcl10 links saturated fat overnutrition with hepatocellular NF-kappaB activation and insulin resistanceCell Rep20121544445222708078
   PubMed Web of Science ®Google Scholar
• JornayvazFRBcl10 and methylation of fatty acids: a future therapeutic target for type 2 diabetes?Clin Lipidol201275493495
   Web of Science ®Google Scholar
• TsuchiyaKTanakaJShuiqingYFoxOs integrate pleiotropic actions of insulin in vascular endothelium to protect mice from atherosclerosisCell Metab201215337238122405072
   PubMed Web of Science ®Google Scholar
• ThorinEVascular disease risk in patients with hypertriglyceridemia: endothelial progenitor cells, oxidative stress, accelerated senescence, and impaired vascular repairCan J Cardiol201127553854021764253
   PubMed Web of Science ®Google Scholar
• KholiPCannonCPTriglycerides: how much credit do they deserve?Med Clin North Am2012961395522391250
   PubMed Web of Science ®Google Scholar
• SprecherDLTargeting triglycerides as prognostic indicators and determining lowest values for patient benefitCurr Cardiol Rep20013542443211504580
   PubMedGoogle Scholar
• BerglundLSacksFBrunzellJDRenewed interest in triglyceridesClin Lipidol20138114
   Web of Science ®Google Scholar
• LeNAWalterMFThe role of hypertriglyceridemia in atherosclerosisCurr Atheroscler Rep20079211011517877919
   PubMedGoogle Scholar
• ChapmanMJGinsbergHNAmarencoPTriglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementEur Heart J201132111345136121531743
   PubMed Web of Science ®Google Scholar
• TalayeroBGSacksFMThe role of triglycerides in atherosclerosisCurr Cardiol Rep201113654455221968696
   PubMedGoogle Scholar
• HavelRJTriglyceride-rich lipoproteins and plasma lipid transportArterioscler Thromb Vasc Biol201030191920018941
   PubMed Web of Science ®Google Scholar
• LarredeSQuinnCMJessupWStimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independentArterioscler Thromb Vasc Biol200929111930193619729607
   PubMed Web of Science ®Google Scholar
• Chinetti-GbaguidiGBaronMBouhlelMAHuman atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathwaysCirc Res2011108898599521350215
   PubMed Web of Science ®Google Scholar
• van HeesAMSarisWHDallinga-ThieGMFasting and postprandial remnant-like particle cholesterol concentrations in obese participants are associated with plasma triglycerides, insulin resistance, and body fat distributionJ Nutr2008138122399240519022964
   PubMed Web of Science ®Google Scholar
• TwicklerTBDallinga-ThieGMCohnJSChapmanMJElevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotypeCirculation2004109161918192515117861
   PubMed Web of Science ®Google Scholar
• SatohAAdachiHTsurutaMHigh plasma level of remnant-like particle cholesterol in the metabolic syndromeDiabetes Care200528102514251816186289
   PubMed Web of Science ®Google Scholar
• de GraafJvan der VleutenGMter AvestEDallinga-ThieGMStalenhoefAFHigh plasma level of remnant-like particles cholesterol in familial combined hyperlipidemiaJ Clin Endocrinol Metab20079241269127517227806
   PubMed Web of Science ®Google Scholar
• Lamon-FavaSHerringtonDMReboussinDMPlasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal womenArterioscler Thromb Vasc Biol200828357557918174456
   PubMed Web of Science ®Google Scholar
• ImkeCRodriguezBLGroveJSAre remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart StudyArterioscler Thromb Vasc Biol20052581718172215947240
   PubMed Web of Science ®Google Scholar
• NaraMSuminoHMachidaTAmagaiHNakajimaKMurakamiMImpaired blood rheology and elevated remnant-like lipoprotein particle cholesterol in hypercholesterolaemic subjectsJ Int Med Res200937230831719383223
   PubMed Web of Science ®Google Scholar
• ZilversmitDBA proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteinsCirc Res19733366336384361710
   PubMed Web of Science ®Google Scholar
• VarboABennMTybjærg-HansenAJørgensenABFrikke-SchmidtRNordestgaardBGRemnant cholesterol as a causal risk factor for ischemic heart diseaseJ Am Coll Cardiol201361442743623265341
   PubMed Web of Science ®Google Scholar
• FaergemanOHolmeIFayyadRPlasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery diseaseAm J Cardiol2009104445946319660594
   PubMed Web of Science ®Google Scholar
• MillerMStoneNJBallantyneCTriglycerides and cardiovascular disease: a scientific statement from the American Heart AssociationCirculation2011123202292233321502576
   PubMed Web of Science ®Google Scholar
• JackeviciusCATuJVRossJSKoDTCarreonDKrumholzHMUse of fibrates in the United States and CanadaJAMA2011305121217122421427374
   PubMed Web of Science ®Google Scholar
• KeechASimesRJBarterPEffects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialLancet200536695001849186116310551
   PubMed Web of Science ®Google Scholar
• GinsbergHNElamMBLovatoLCEffects of combination lipid therapy in type 2 diabetes mellitusN Engl J Med2010362171563157420228404
   PubMed Web of Science ®Google Scholar
• DavisTMTingRBestJDEffects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) StudyDiabetologia201154228029021052978
   PubMed Web of Science ®Google Scholar
• TingRDKeechACDruryPLBenefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD studyDiabetes Care201235221822522210576
   PubMed Web of Science ®Google Scholar
• MakiKCBaysHEDicklinMRTreatment options for the management of hypertriglyceridemia: strategies based on the best-available evidenceJ Clin Lipidol120126541342623009777
   PubMed Web of Science ®Google Scholar
• RainwaterDLMcMahanCAMalcomGTLipid and apolipoprotein predictors of atherosclerosis in youth: apolipoprotein concentrations do not materially improve prediction of arterial lesions in PDAY subjectsArterioscler Thromb Vasc Biol199919375376110073983
   PubMed Web of Science ®Google Scholar
• RobinsonJGWangSSmithBJJacobsonTAMeta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease riskJ Am Coll Cardiol200953431632219161879
   PubMed Web of Science ®Google Scholar
• LiuJSemposCDonahueRPDornJTrevisanMGrundySMJoint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetesDiabetes Care20052881916192116043732
   PubMed Web of Science ®Google Scholar
• FrostPHDavisBRBurlandoAJSerum lipids and incidence of coronary heart disease: findings from the Systolic Hypertension in the Elderly Program (SHEP)Circulation19969410238123888921777
   PubMed Web of Science ®Google Scholar
• MasanaLIbarretxeDHerasMSubstituting non-HDL cholesterol with LDL as a guide for lipid-lowering therapy increases the number of patients with indication for therapyAtherosclerosis2013226247147523290265
   PubMed Web of Science ®Google Scholar
• CuiYBlumenthalRSFlawsJANon-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortalityArch Intern Med2001161111413141911386890
   PubMedGoogle Scholar
• BittnerVHardisonRKelseySWeinerBHJacobsAKSopkoGNon-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI)Circulation2002106202537254212427648
   PubMed Web of Science ®Google Scholar
• RidkerPMRifaiNCookNRBradwinGBuringJENon-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in womenJAMA2005294332633316030277
   PubMed Web of Science ®Google Scholar
• RamjeeVSperlingLSJacobsonTANon-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the mathJ Am Coll Cardiol201158545746321777740
   PubMed Web of Science ®Google Scholar
• SnidermanADWilliamsKContoisJMA meta-analysis of LDL-C, non-HDL-C and apoB as markers of cardiovascular riskCirc Cardiovasc Qual Outcomes20114333734521487090
   PubMed Web of Science ®Google Scholar
• SnidermanADSt-PierreACantinBConcordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic riskAm J Cardiol200391101173117712745098
   PubMed Web of Science ®Google Scholar
• SnidermanADIslamSYusufSMcQueenMJDiscordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART studyAtherosclerosis2012225244444923068583
   PubMed Web of Science ®Google Scholar
• BoekholdtSMArsenaultBJMoraSJAMA2012307121302130922453571
   PubMed Web of Science ®Google Scholar
• MahajanNFerenceBAAroraNRole of non-high-density lipoprotein cholesterol in predicting cerebrovascular events in patients following myocardial infarctionAm J Cardiol2012109121694169922465317
   PubMed Web of Science ®Google Scholar
• BrunzellJDDavidsonMFurbergCDLipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology FoundationJ Am Coll Cardiol200851151512152418402913
   PubMed Web of Science ®Google Scholar
• QuertonLBuysschaertMHermansMPHypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levelsJ Clin Lipidol20126543444223009779
   PubMed Web of Science ®Google Scholar
• JacobsonTA‘Trig-onometry’: non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemiaInt J Clin Pract20116518210121105969
   PubMed Web of Science ®Google Scholar
• ViraniSSImplementation Strategies to Improve Non-HDL-Cholesterol Goal Attainment. Current Evidence and a Conceptual Framework for Future DirectionsTex Heart Inst J201239222823022740738
   PubMed Web of Science ®Google Scholar
• RanaJSBoekholdtSMKasteleinJJPShahPKThe role of non-HDL cholesterol in risk stratification for coronary artery diseaseCurr Atheroscler Rep201214213013422203405
   PubMed Web of Science ®Google Scholar
• SnidermanADWilliamsKContoisJHA meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular riskCirc Cardiovasc Qual Outcomes20114333734521487090
   PubMed Web of Science ®Google Scholar
• TallARCholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteinsJ Intern Med2008263325627318271871
   PubMed Web of Science ®Google Scholar
• MorganJMCapuzziDMBakshRIEffects of extended-release niacin on lipoprotein subclass distributionAm J Cardiol200391121432143612804729
   PubMed Web of Science ®Google Scholar
• RingseisRRosenbaumSGessnerDKSupplementing obese Zucker rats with niacin induces the transition of glycolytic to oxidative skeletal muscle fibersJ Nutr2013143212513123256146
   PubMed Web of Science ®Google Scholar
• ChoiSYoonHOhKSWidespread effects of nicotinic acid on gene expression in insulin-sensitive tissues: implications for unwanted effects of nicotinic acid treatmentMetabolism201160113414420303128
   PubMed Web of Science ®Google Scholar
• KamannaVSGanjiSHKashyapMLRecent advances in niacin and lipid metabolismCurr Opin Lipidol201324323924523619367
   PubMed Web of Science ®Google Scholar
• Lamon-FavaSDiffenderferMRBarrettPHExtended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteinsArterioscler Thromb Vasc Biol20082891672167818566298
   PubMed Web of Science ®Google Scholar
• LukasovaMMalavalCGilleAKeroJOffermannsSNicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cellsJ Clin Invest201112131163117321317532
   PubMed Web of Science ®Google Scholar
• Yvan-CharvetLKlingJPaglerTCholesterol efflux potential and anti-inflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapibArterioscler Thromb Vasc Biol20103071430143820448206
   PubMed Web of Science ®Google Scholar
• BodenWEProbstfieldJLAndersonTNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med2011365242255226722085343
   PubMed Web of Science ®Google Scholar
• LavignePMKarasRHThe current state of niacin in cardiovascular disease prevention: a systematic review and meta-regressionJ Am Coll Cardiol201361444044623265337
   PubMed Web of Science ®Google Scholar
• WuBJYanLCharltonFWittingPBarterPJRyeKAEvidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipidsArterioscler Thromb Vasc Biol201030596897520167660
   PubMed Web of Science ®Google Scholar
• HolzhäuserEAlbrechtCZhouQNicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilitiesJ Cardiovasc Pharmacol201157444745421242806
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govTreatment of HDL to reduce the incidence of vascular events HPS2-THRIVE4172007 Available from: http://clinicaltrials.gov/show/NCT00461630Accessed June 20, 2013
   Google Scholar
• HPS2-THRIVE Collaborative GroupHPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatmentEur Heart J201334171279129123444397
   PubMed Web of Science ®Google Scholar
• MerckMerck announces HPS2-THRIVE study of Tredaptive (extended-release niacin/laropiprant) did not achieve primary endpoint12202012 Available from: http://www.mercknewsroom.com/press-release/prescription-medicine-news/merck-announces-hps2-thrive-study-tredaptive-extended-releaAccessed June 20, 2013
   Google Scholar
• O’RiordanMIf not dead, not healthy : Niacin full results in HPS2-THRIVE aired at ACC Available from: http://www.theheart.org/article/1515533.doAccessed June 10, 2013
   Google Scholar
• van der SteegWAHolmeIBoekholdtSMHigh-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular riskJ Am Coll Cardiol200851663464218261682
   PubMed Web of Science ®Google Scholar
• BarterPJCaulfieldMErikssonMEffects of torcetrapib in patients at high risk for coronary eventsN Engl J Med2007357212109212217984165
   PubMed Web of Science ®Google Scholar
• BarterPRyeKACholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now?Trends Pharmacol Sci2011321269469922088767
   PubMed Web of Science ®Google Scholar
• de HaanJde Vries-van der WeijJvan der HoornJTorcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatinCirculation2008117192515252218458167
   PubMed Web of Science ®Google Scholar
• SchwartzGGOlssonAGBallantyneCMRationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndromeAm Heart J2009158689690119958854
   PubMed Web of Science ®Google Scholar
• FayadZAManiVWoodwardMSafety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trialLancet201137898021547155921908036
   PubMed Web of Science ®Google Scholar
• LüscherTFTaddeiSKaskiJCVascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trialEur Heart J201233785786522345126
   PubMed Web of Science ®Google Scholar
• ClarkRWRuggeriRBCunninghamDDescription of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of actionJ Lipid Res2006473536552
   Web of Science ®Google Scholar
• CannonCPShahSDanskyHMSafety of anacetrapib in patients with or at high risk for coronary heart diseaseN Engl J Med2010363252406241521082868
   PubMed Web of Science ®Google Scholar
• NichollsSJBrewerHBKasteleinJJEffects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol. A randomized controlled trialJAMA2011306192099210922089718
   PubMed Web of Science ®Google Scholar
• JohannsenTHFrikke-SchmidtRSchoouJNordestgaardBGTybjærg-HansenAGenetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effectsJ Am Coll Cardiol201260202041204823083790
   PubMed Web of Science ®Google Scholar
• PlutzkyJThe PPAR-RXR transcriptional complex in the vasculature: energy in the balanceCirc Res201110881002101621493923
   PubMed Web of Science ®Google Scholar
• StaelsBDallongevilleJAuwerxJSchoonjansKLeitersdorfEFruchartJCMechanism of action of fibrates on lipid and lipoprotein metabolismCirculation19989819208820939808609
   PubMed Web of Science ®Google Scholar
• LalloyerFStaelsBFibrates, glitazones, and peroxisome proliferator-activated receptorsArterioscler Thromb Vasc Biol201030589489920393155
   PubMed Web of Science ®Google Scholar
• LefebvrePChinettiGFruchartJCStaelsBSorting out the roles of PPAR alpha in energy metabolism and vascular homeostasisJ Clin Invest2006116357158016511589
   PubMed Web of Science ®Google Scholar
• TorraIPChinettiGDuvalCFruchartJCStaelsBPeroxisome proliferator-activated receptors: from transcriptional control to clinical practiceCurr Opin Lipidol200112324525411353326
   PubMed Web of Science ®Google Scholar
• RosensonRSWrightRSFarkouhMPlutzkyJModulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospectsAm Heart J2012164567268023137497
   PubMed Web of Science ®Google Scholar
• WattsGFStaelsBRegulation of endothelial nitric oxide synthase by PPAR agonists: molecular and clinical perspectivesArterioscler Thromb Vasc Biol200424461962115059810
   PubMed Web of Science ®Google Scholar
• GoyaKSumitaniSXuXPeroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cellsArterioscler Thromb Vasc Biol200424465866314751809
   PubMed Web of Science ®Google Scholar
• DelerivePDe BosscherKBesnardSPeroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1J Biol Chem199927475320483205410542237
   PubMedGoogle Scholar
• GlineurCGrossBNeveGFenofibrate inhibits endothelin-1 expression by peroxisome proliferator-activated receptor α-dependent and independent mechanisms in human endothelial cellsArterioscler Thromb Vasc Biol201333362162823329136
   PubMed Web of Science ®Google Scholar
• McCulloughPAAhmedAZughaibMGlanzEDiLorentoMTreatment of hypertriglyceridemia with fibric acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular eventsRev Cardiovasc Med201112417318522249508
   PubMed Web of Science ®Google Scholar
• ManninenVTenkanenLKoskinenPJoint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatmentCirculation199285137451728471
   PubMed Web of Science ®Google Scholar
• FrickMHEloOHaapaKHelsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart diseaseN Engl J Med198731720123712453313041
   PubMed Web of Science ®Google Scholar
• TenkanenLMänttäriMKovanenPTVirkkunenHManninenVGemfibrozil in the Treatment of Dyslipidemia: An 18-Year Mortality Follow-up of the Helsinki Heart StudyArch Intern Med2006166774374816606810
   PubMedGoogle Scholar
• RubinsHBRobinsSJCollinsDGemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study GroupN Engl J Med1999341641041810438259
   PubMed Web of Science ®Google Scholar
• RobinsSJCollinsDWittesJTVA-HIT Study GroupRelation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trialJAMA2001285121585159111268266
   PubMed Web of Science ®Google Scholar
• BIP Study GroupSecondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) studyCirculation20001021212710880410
   PubMed Web of Science ®Google Scholar
• ScottRO’BrienRFulcherGFenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study InvestigatorsEffects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) studyDiabetes Care200932349349818984774
   PubMed Web of Science ®Google Scholar
• TonkinAMChenLEffects of Combination Lipid Therapy in the Management of Patients With Type 2 Diabetes Mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) TrialCirculation2010122885085220733114
   PubMed Web of Science ®Google Scholar
• Reyes-SofferGNgaiCLLovatoLEffect of fenofibrate-simvistatin on postprandial (PP) lipid and lipoprotein levels in a subgroup of patients in the ACCORD Lipid trialDiabetes Care201336242242823033246
   PubMed Web of Science ®Google Scholar
• ColhounHAfter FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?Lancet200536695001829183116310536
   PubMed Web of Science ®Google Scholar
• JunMFooteCLvJEffects of fibrates on cardiovascular outcomes: a systematic review and meta-analysisLancet201037597291875188420462635
   PubMed Web of Science ®Google Scholar
• SacksFMCareyVJFruchartJCCombination lipid therapy in type 2 diabetesN Engl J Med2010363769269420842772
   PubMed Web of Science ®Google Scholar
• LeeMSaverJLTowfighiAChowJOvbiageleBEfficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysisAtherosclerosis2011217249249821592479
   PubMed Web of Science ®Google Scholar
• BallantyneCMJonesPHKellyMTLong-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglyceridesCardiovasc Drugs Ther2011251s59s67
   PubMed Web of Science ®Google Scholar
• TenenbaumAFismanEZFibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reductionCardiovasc Diabetol20121112523057687
   PubMed Web of Science ®Google Scholar
• TeramotoTShiraiKDaidaHYamadaNEffects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT studyCardiovasc Diabetol2012112922439599
   PubMed Web of Science ®Google Scholar
• Roche media releaseBasel7102013 Available at http://www.roche.com/media/media_releases/med-cor-2013-07-10.htmAccessed September 10, 2013
   Google Scholar
• ZhaoYYWeirMAMannoMNew fibrate use and acute renal outcomes in elderly adults: a population-based studyAnn Intern Med2012156856056922508733
   PubMed Web of Science ®Google Scholar
• JunMZhuBTonelliMEffects of fibrates in kidney disease. A systematic review and meta-analysisJ Am Coll Cardiol201260202061207123083786
   PubMed Web of Science ®Google Scholar
• ChenYLHsuCYHuangWCFenofibrate reversibly increases serum creatinine level in chronic kidney disease patients by reducing glomerular filtration rate. http://webcache.googleusercontent.com/search?q=cache;http://ir.cmu.edu.tw/ir/bitstream/310903500/40684/1/20110412154428.pdfActa Nephrologica201125114
   Google Scholar
• LipscombeJLewisGFCattranDDeterioration in renal function associated with fibrate therapyClin Nephrol2001551394411200866
   PubMed Web of Science ®Google Scholar
• MychaleckyjJCCravenTNayakUReversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participantsDiabetes Care20123551008101422432114
   PubMed Web of Science ®Google Scholar
• BloomfieldHEThe role of fibrates in a statin worldArch Intern Med2006166771571616606806
   PubMedGoogle Scholar
• MaranghiMHiukkaABadeauRSundvallJJauhiainenMTaskinenMRMacrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: a FIELD substudyAtherosclerosis2011219125926521696738
   PubMed Web of Science ®Google Scholar
• KrysiakROkopienBEffect of benzafibrate on monocyte cytokine release and systemic inflammation in patients with impaired fasting glucoseJ Clin Pharmacol201151101459146721119093
   PubMed Web of Science ®Google Scholar
• DavidsonMRosensonRSMakiKCStudy design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trialCar-diovasc Drugs Ther2012264349358
   PubMed Web of Science ®Google Scholar
• GoldfineABKaulSHiattWRFibrates in the treatment of dyslipidemias – time for a reassessmentN Engl J Med2011365648148421830963
   PubMed Web of Science ®Google Scholar
• DowningNSRossJSJackeviciusCAKrumholzHMAvoidance of generic competition by Abbott Laboratories’ fenofibrate franchiseArch Intern Med2012172972473022493409
   PubMedGoogle Scholar
• Food and Drug AdministrationFDA Drug Safety Communication: Review update of Trilipix (fenofibric acid) and the ACCORD Lipid trial1192011 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm278837.htmAccessed June 20, 2013
   Google Scholar
• GrundySMCleemanJIMerzCNNational Heart, Lung, and Blood Institute: American College of Cardiology; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesCirculation2004110222722915249516
   PubMed Web of Science ®Google Scholar
• ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)Atherosclerosis2011217114421722901
   PubMed Web of Science ®Google Scholar
• BerglundLBrunzellJDGoldbergACEvaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guidelineJ Clin Endocrinol Metab20129792969298922962670
   PubMed Web of Science ®Google Scholar
• YusufSHawkenSOunpuuSEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyLancet2004364943893795215364185
   PubMed Web of Science ®Google Scholar
• KotsevaKWoodDDe BackerGCardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countriesLancet2009373966792994019286092
   PubMed Web of Science ®Google Scholar
• MoraSWengerNKDeMiccoDADeterminants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy. The treating to new targets (TNT) studyCirculation2012125161979198722461416
   PubMed Web of Science ®Google Scholar
• AfonsoLVeerannaVZalawadiyaSRameshKNirajAPanaichSPredictors of residual cardiovascular risk in patients on statin therapy for primary preventionCardiology2011119418719021968436
   PubMed Web of Science ®Google Scholar
• RayKKCannonCPCairnsRMorrowDARidkerPMBraunwaldEPrognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22Arte-rioscler Thromb Vasc Biol2009293424430
   PubMed Web of Science ®Google Scholar
• DrexelHAczelSMarteTVonbankASaelyCHFactors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosisAtherosclerosis2010208248448919748621
   PubMed Web of Science ®Google Scholar
• HaywardRAKrumholzRMThree reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of HealthCirc Cardiovasc Qual Outcomes2012512522253366
   PubMed Web of Science ®Google Scholar
• StoneNJReducing residual risk in secondary prevention of cardiovascular diseaseCirculation2012125161958196022461417
   PubMed Web of Science ®Google Scholar
• BlaschkeTFOsterbergLVrijensBUrquhartJAdherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing historiesAnnu Rev Pharmacol Toxicol20125227530121942628
   PubMed Web of Science ®Google Scholar
• GrangerBBBosworthHBMedication adherence: emerging use of technologyCurr Opin Cardiol2011262427928721597368
   PubMedGoogle Scholar
• StegPGAlamSChiangCESymptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the Realise AF cross-sectional international registryHeart201298919520121948959
   PubMedGoogle Scholar
• JackeviciusCAMamdaniMTuJVAdherence with statin therapy in elderly patients with and without acute coronary syndromesJAMA2002288446246712132976
   PubMed Web of Science ®Google Scholar
• LardizabalJADeedwaniaPCBenefits of statin therapy and compliance in high risk cardiovascular patientsVasc Health Risk Manag2010684385320957130
   PubMedGoogle Scholar
• HoPMMagidDJShetterlySMMedication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery diseaseAm Heart J2008155477272918371492
   PubMed Web of Science ®Google Scholar
• DonnellyLADoneyASMorrisADPalmerCNConnanPTLong-term adherence to statin treatment in diabetesDiabet Med200825785085518644071
   PubMed Web of Science ®Google Scholar
• ArnoldSVSpertusJATangFStatin use in outpatients with obstructive coronary artery diseaseCirculation2011124222405241022064595
   PubMed Web of Science ®Google Scholar
• HlatkyMASolomonMDShilaneDLeongTKBrindisRGoASUse of medications for secondary prevention after coronary bypass surgery compared with percutaneous coronary interventionJ Am Coll Cardiol201361329530123246391
   PubMed Web of Science ®Google Scholar
• StanekEJSarawateCWilleyVJCharlandSLCzirakyMJRisk of cardiovascular events in patients at optimal values for combined lipid parametersCurr Med Res Opin200723355356317357251
   PubMed Web of Science ®Google Scholar
• CzirakyMJTanHBullanoMFYuJSchiebingerRWilleyVJImpact of optimal lipid value achievement between 2005 and 2009 in patients with mixed dyslipidaemia on cardiovascular event ratesInt J Clin Pract201165442543521401832
   PubMed Web of Science ®Google Scholar
• ChoudhryNKAvomJGlynnRJFull coverage for preventive medications after myocardial infarctionN Engl J Med2011365222088209722080794
   PubMed Web of Science ®Google Scholar
• BodenWECOURAGE 5 years on. The message grows strongerHeart201298241757176023204531
   PubMed Web of Science ®Google Scholar
• FihnSDGardinJMAbramsJ2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic SurgeonsCirculation20121263097313723166210
   PubMed Web of Science ®Google Scholar
• BordenWBRedbergRFMushlinAIPatterns and intensity of medical therapy in patients undergoing percutaneous coronary interventionJAMA2011305181882188921558519
   PubMed Web of Science ®Google Scholar
• HannanELSamadashviliZCozzensKComparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New YorkCirculation2012125151870187922441935
   PubMed Web of Science ®Google Scholar
• BodenWEMounting evidence for lack of PCI benefit in stable ischemic heart disease: what more will it take to turn the tide of treatment?Arch Intern Med2012172431932122371920
   PubMedGoogle Scholar
• BodenWEWhich is more enduring – FAME or COURAGE?N Engl J Med2012367111059106122924622
   PubMed Web of Science ®Google Scholar
• VulicDLeeBTDedeJLopezVAWongNDExtent of control of cardiovascular risk factors and adherence to recommended therapies in US multiethnic adults with coronary heart disease: from a 2005–2006 national surveyAm J Cardiovasc Drugs201010210911420334448
   PubMed Web of Science ®Google Scholar
• KumbhaniDJFonarowGCCannonCPPredictors of adherence to performance measures in patients with acute myocardial infarctionAm J Med2013126174. e174. e922925314
   PubMed Web of Science ®Google Scholar
• GottoAMJrImproving lipid goal attainment: is it enough?Circulation200912016819546382
   PubMed Web of Science ®Google Scholar
• SarawateCACzirakyMJStanekEJWilleyVJCorbelliJCCharlandSLAchievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?Clin Ther200729119620917379061
   PubMed Web of Science ®Google Scholar
• GeorgePBTobinKJCorpusRADevlinWHO’NeillWWTreatment of cardiac risk factors in diabetic patients: how well do we follow the guidelines?Am Heart J2001142585786311685175
   PubMed Web of Science ®Google Scholar
• GittAKDrexelHFeelyJPersistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and CanadaEur J Prev Cardiol201219222123021450578
   PubMed Web of Science ®Google Scholar
• VedinOHagströmEStewartRSecondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY studyEur J Prev Cardiol4102013 [Epub ahead of print.]
   PubMed Web of Science ®Google Scholar
• KotsevaKJenningsCSTurnerELASPIRE-2-PREVENT: a survey of lifestyle, risk factor management and cardioprotective medication in patients with coronary heart disease and people at high risk of developing cardiovascular disease in the UKHeart2012981186587122581735
   PubMed Web of Science ®Google Scholar
• LaforestLAmbegaonkarBMSouchetTSazonovVVan GanseRMixed dyslipidemias in primary care patients in FranceVasc Health Risk Manage20128247254
   PubMedGoogle Scholar
• FerrièresJElbazMMaupasECarrièDPuelJInadequate management of dyslipidaemic patients in France. Results of the Odyssée studyArch Mal Coeur Vaiss2004973187193 French15106741
   PubMedGoogle Scholar
• Alsheikh-AliAALinJLAbourjailyPAhearnDKuvinJTKarasRHPrevalence of low high-density lipoprotein cholesterol in patients with documented coronary high disease or risk equivalent and controlled low-density lipoprotein cholesterolAm J Cardiol2007100101499150117996508
   PubMed Web of Science ®Google Scholar
• IshisakaDYJukesTRomanelliRJWongKSSchiroTADisparities in adherence to and persistence with antihypertensive regimens: an exploratory analysis from a community-based provider networkJ Am Soc Hypertens20126320120922520931
   PubMed Web of Science ®Google Scholar
• HillMNMillerNHDegeestSAdherence and persistence with taking medication to control high blood pressureJ Am Soc Hypertens201151566321320699
   PubMed Web of Science ®Google Scholar
• GlynnLGMurphyAWSmithSMInterventions used to improve control of blood pressure in patients with hypertensionCochrane Database Syst Rev20103CD0005182
   Google Scholar
• SabateEWorld Health OrganizationAdherence to Long Term Therapies: Evidence for ActionGenevaWorld Health Organization2003
   Google Scholar
• PhillipsLSTwomblyJGIt’s time to overcome clinical inertiaAnn Intern Med20081481078378518490691
   PubMed Web of Science ®Google Scholar
• HauebschmannAGMizrahiTSoenksenABeatyBLDenbergTDReducing clinical inertia in hypertension treatment: a pragmatic randomized controlled trialJ Clin Hypertens2012145322329
   Web of Science ®Google Scholar
• RiveraCMSongJCopelandLBirgeCOryMMcNealCJUnderuse of aspirin for primary and secondary prevention of cardiovascular disease events in womenJ Womens Health (Larchmt)201221437938722303820
   PubMed Web of Science ®Google Scholar
• CheungBMOngKLChernySSShamPCTsoAWLamKSDiabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006Am J Med2009122544345319375554
   PubMed Web of Science ®Google Scholar
• JohnsonMLPietzKBattlemanDSBeythRJPrevalence of comorbid hypertension and dyslipidemia and associated cardiovascular diseaseAm J Manag Care2004101292693215617368
   PubMed Web of Science ®Google Scholar
• StolarMWDefining and achieving treatment success in patients with type 2 diabetes mellitusMayo Clin Proc201085Suppl 12S50S5921106864
   PubMedGoogle Scholar
• WongNDGlovaciDWongKGlobal cardiovascular disease risk assessment in United States adults with diabetesDiab Vasc Dis Res201291214615222377485
   PubMedGoogle Scholar
• CasagrandeSSFradkinJESaydahSHRustKFCowieCCThe prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010Diabetes Care2152013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• YusufSIslamSChowCKUse of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological surveyLancet2011378111231124321872920
   PubMedGoogle Scholar
• KingDEMainousAG3rdGeeseyMTurning back the clock: adopting a healthy lifestyle in middle-ageAm J Med2007120759860317602933
   PubMed Web of Science ®Google Scholar
• MozaffarianDAfshinABenowitzNLPopulation approaches to improve diet, physical activity, and smoking habits. A scientific statement from the American Heart AssociationCirculation2012126121514156322907934
   PubMed Web of Science ®Google Scholar
• KotkeTEReversing the slide in US health outcomes and deteriorating health care economicsMayo Clin Proc201388653353523726396
   PubMed Web of Science ®Google Scholar
• JonesDSGreeneJAThe contributions of prevention and treatment to the decline in cardiovascular mortality: lessons from a forty-year debateHealth Aff (Millwood)201231102250102258
   Web of Science ®Google Scholar
• WebberBJSeguinPGBurnettDGClarkLLOttoJLPrevalence of and risk factors for autopsy-determined atherosclerosis among US service members, 2001–2011JAMA2012308242577258323268516
   PubMed Web of Science ®Google Scholar
• KottkeTEFaithDAJordanCOPronkNPThomasRJCapewellSThe comparative effectiveness of heart disease prevention and treatment strategiesAm J Prev Med2009361828819095166
   PubMed Web of Science ®Google Scholar
• GoASMozaffarianDRogerVLHeart and stroke statistics – 2013 update: a report from the American Heart AssociationCirculation20131271e6e24523239837
   PubMed Web of Science ®Google Scholar
• CapewellSFordESCroftJBCritchleyJAGreenlundKJLabartheDRCardiovascular risk factor trends and potential for reducing coronary heart disease mortality in the United States of AmericaBull World Health Organ201088212013020428369
   PubMed Web of Science ®Google Scholar
• YoungFCapewellSFordESCritchleyJACoronary mortality declines in the US between 1980 and 2000: quantifying the contributions from primary and secondary preventionAm J Prev Med201039322823420709254
   PubMed Web of Science ®Google Scholar
• KonesRRecent advances in the management of chronic stable angina. II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularizationVasc Health Risk Manag2010674977420859545
   PubMedGoogle Scholar
• MontgomeryJEBrownJRMetabolic biomarkers for predicting cardiovascular diseaseVasc Health Risk Manag20139374523386789
   PubMedGoogle Scholar
• KingDEMainousAGIIIMathesonEMEverettCJImpact of healthy lifestyle on mortality in people with normal blood pressure, LDL cholesterol, and C-reactive proteinEur J Cardiovasc Prev Rehabil20132017379
   Google Scholar
• BerryJDDyerACaiXLifetime risks of cardiovascular diseaseN Engl J Med2012366432132922276822
   PubMed Web of Science ®Google Scholar
• DehghanMMenteATeoKKBehalf of the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)/Telmisartan Randomized Assessment Study in ACEI Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Trial InvestigatorsRelationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countriesCirculation2012126232705271223212996
   PubMed Web of Science ®Google Scholar
• KantAKSchatzkinAGraubardBISchairerCA prospective study of diet quality and mortality in womenJAMA2000283162109211510791502
   PubMed Web of Science ®Google Scholar
• BarziFWoodwardMMarfisiRMTavazziLValagussaFMarchioliRMediterranean diet and all-causes mortality after myocardial infarction: results from the GISSI-Prevenzione trialEur J Clin Nutr200357460461112700623
   PubMed Web of Science ®Google Scholar
• de LorgerilMSalenPMartinJLMonjaudIDelayeJMamelleNMediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart StudyCirculation19999967797859989963
   PubMed Web of Science ®Google Scholar
• Lloyd-JonesDMLarsonMGBeiserALevyDLifetime risk of developing coronary heart diseaseLancet19993539147899210023892
   PubMed Web of Science ®Google Scholar
• Lloyd-JonesDMLeipEPLarsonMGPrediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of ageCirculation2006113679179816461820
   PubMed Web of Science ®Google Scholar
• WilkinsJTNingHBerryJZhaoLDyerARLloyd-JonesDMLifetime risk and years lived free of total cardiovascular diseaseJAMA2012308171795180123117780
   PubMed Web of Science ®Google Scholar
• BerryJDWillisBGuptaSLifetime risks for cardiovascular disease mortality by cardiorespiratory fitness levels measured at ages 45, 55, and 65 years in menJ Am Coll Cardiol201157151604161021474041
   PubMed Web of Science ®Google Scholar
• JonesDSPodolskySHGreeneJAThe burden of disease and the changing task of medicineN Engl J Med2012366252333233822716973
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention, National Center for Health StatisticsHealthUnited States2011 Available from: http://www.cdcgov/nchs/hus.htmAccessed June 20, 2013
   Google Scholar
• FangJYangQHongYLoustalotFStatus of cardiovascular health among adult Americans in the 50 States and the District of Columbia, 2009J Am Heart Assoc201216e00537123316331
   PubMed Web of Science ®Google Scholar
• ShayCMNingHDanielsSRRooksCRGiddingSSLloyd-JonesDMStatus of cardiovascular health in US adolescents: prevalence estimates from the National Health and Nutrition Examination Surveys (NHANES) 2005–2010Circulation2013127131369137623547177
   PubMed Web of Science ®Google Scholar
• van DamRMWillettWCUnmet potential for cardiovascular disease prevention in the United StatesCirculation2009120131171117319752318
   PubMed Web of Science ®Google Scholar
• TrichopoulouACostacouTBamiaCTrichopoulosDAdherence to a Mediterranean diet and survival in a Greek populationN Engl J Med2003348262599260812826634
   PubMed Web of Science ®Google Scholar
• SofiFCesariFAbbateRGensiniGFCasiniAAdherence to Mediter-ranean diet and health status: meta-analysisBMJ2008337a134418786971
   PubMed Web of Science ®Google Scholar
• FungTTRexrodeKMMantzorosCSMediterranean diet and incidence of and mortality from coronary heart disease and stroke in WomenCirculation200911681093110019221219
   PubMedGoogle Scholar
• Martínez-GonzálezMAGarcía-LópezMBes-RastrolloMMediterranean diet and the incidence of cardiovascular disease: a Spanish cohortNutr Metab Cardiovasc Dis201121423724420096543
   PubMed Web of Science ®Google Scholar
• EstruchRRosESalas-SalvadóJPrimary prevention of cardiovascular disease with a Mediterranean dietN Engl J Med2013368141279129023432189
   PubMed Web of Science ®Google Scholar
• Bibbins-DomingoKChertowGMCoxsonPGProjected effect of dietary salt reductions on future cardiovascular diseaseN Engl J Med2010362759059920089957
   PubMed Web of Science ®Google Scholar
• CoxsonPGCookNRJoffresMMortality benefits from US population-wide reduction in sodium consumption. Projections from 3 modeling approachesHypertension201361356457023399718
   PubMed Web of Science ®Google Scholar
• NordestgaardBGPalmerTMBennMThe effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approachPLoS Med201295e100121222563304
   PubMed Web of Science ®Google Scholar
• CritchleyJCapewellSMortality risk reduction associated with smoking cessation in patients with coronary heart disease. A systematic reviewJAMA20032901869712837716
   PubMed Web of Science ®Google Scholar
• ShephardRJLimits to the measurement of habitual physical activity by questionnairesBr J Sports Med200337319720612782543
   PubMed Web of Science ®Google Scholar
• TroianoRPBerriganBDoddKWMasseLCTilertTMcDowellMPhysical activity in the United States measured by accelerometerMed Sci Sports Exerc200840118118818091006
   PubMed Web of Science ®Google Scholar
• NelsonRHHyperlipidemia as a risk factor for cardiovascular diseasePrim Care201340119521123402469
   PubMed Web of Science ®Google Scholar
• DurringtonPDyslipidemiaLancet2003362938571773112957096
   PubMed Web of Science ®Google Scholar
• JohansenMEGoldKJSenAAratoNGreenLAA national survey of the treatment of hyperlipidemia in primary preventionJAMA Intern Med2013173758658823478751
   PubMed Web of Science ®Google Scholar
• YangQCogswellMEFlandersWDTrends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adultsJAMA2012307121273128322427615
   PubMed Web of Science ®Google Scholar
• ZhangWLiNPrevalence, risk factors, and management of prehypertensionInt J Hypertens2011201160535922121474
   PubMedGoogle Scholar
• BennMTybjærg-HansenAMcCarthyMIJensenGBGrandePNordestgaardBGNonfasting glucose, ischemic heart disease, and myocardial infarction: a Mendelian randomization studyJ Am Coll Cardiol201259252356236522698489
   PubMed Web of Science ®Google Scholar
• WingRRLong-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: 4-year results of the Look AHEAD trialArch Intern Med2010170171566157520876408
   PubMedGoogle Scholar
• GreggEWChenHWagenknechtLEAssociation of an intensive lifestyle intervention with remission of type 2 diabetesJAMA2012308232489249623288372
   PubMed Web of Science ®Google Scholar
• 461 National Institutes of HealthWeight loss does not lower heart disease risk from type 2 diabetes Available from: http://www.nih.gov/news/health/oct2012/niddk-19.htmAccessed June 20, 2013
   Google Scholar
• KnowlerWCBarrett-ConnorEFowlerSEReduction in the incidence of type 2 diabetes with lifestyle intervention or metforminN Engl J Med2002346639340311832527
   PubMed Web of Science ®Google Scholar
• MaJYankVXiaoLTranslating the diabetes prevention program lifestyle intervention for weight loss into primary care: a randomized trialJAMA Intern Med2013173211312123229846
   PubMed Web of Science ®Google Scholar
• CarlssonLMPeltonenMAhlinSBariatric surgery and prevention of type 2 diabetes in Swedish obese subjectsN Engl J Med2012367869570422913680
   PubMed Web of Science ®Google Scholar
• Lloyd-JonesDMHongYLabartheDDefining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s Strategic Impact Goal through 2020 and beyondCirculation2010121458661320089546
   PubMed Web of Science ®Google Scholar
• BambsCKipKEDingaAMulukutlaSRAierANReisSELow prevalence of “Ideal Cardiovascular Health” in a community-based population. The Heart Strategies Concentrating on Risk Evaluation (Heart SCORE) StudyCirculation2011123885085721321154
   PubMed Web of Science ®Google Scholar
• FolsomARYatsayaHNettletonJALutseyPLCushmanMRosamondWDCommunity prevalence of Ideal Cardiovascular Health, by the American Heart Association definition, and relationship with cardiovascular disease incidenceJ Am Coll Cardiol201157161690169621492767
   PubMed Web of Science ®Google Scholar
• ShayCMNingHAllenNBStatus of cardiovascular health in US adults. Prevalence estimates from the National Health and Nutrition Examination Surveys (NHANES) 2003–2008Circulation20121251455622095826
   PubMed Web of Science ®Google Scholar
• FordESGreenlundKJHongYIdeal cardiovascular health and mortality from all causes and diseases of the circulatory system among adults in the United StatesCirculation2012125898799522291126
   PubMed Web of Science ®Google Scholar
• HuffmanMDCapewellSNingHShayCMFordESLloyd-JonesDMCardiovascular health behavior and health factor changes (1988–2008) and projections to 2020: results from the National Health and Nutrition Examination SurveysCirculation2012125212595260222547667
   PubMed Web of Science ®Google Scholar
• WeintraubWSDanielsSRBurkeLEValue of primordial and primary prevention for cardiovascular disease. A policy statement from the American Heart AssociationCirculation2011124896799021788592
   PubMed Web of Science ®Google Scholar
• LiuKDaviglusMLLoriaCMHealthy lifestyle through young adulthood and the presence of low cardiovascular disease risk profile in middle age: the Coronary Artery Risk Development in (Young) Adults (CARDIA) studyCirculation20121258996100422291127
   PubMed Web of Science ®Google Scholar
• HeidenreichPATrogdonJGKhavjouOAForecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart AssociationCirculation2011123893394421262990
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionMillion Hearts: strategies to reduce the prevalence of leading cardiovascular disease risk factors, 2011MMWR Morb Mortal Wkly Rep201160361248125121918495
   PubMedGoogle Scholar
• FriedenTRBerwickDMThe “Million Hearts” initiative – preventing heart attacks and strokesN Engl J Med201136513e2721913835
   PubMed Web of Science ®Google Scholar
• TomaselliGFHartyMBHortonKSchoeberlMThe American Heart Association and the Million Hearts Initiative: a presidential advisory from the American Heart AssociationCirculation2011124161795179921914834
   PubMed Web of Science ®Google Scholar
• RogerVLO’DonnellCJPopulation health, outcomes research, and prevention. Example of the American Heart Association 2020 goalsCirc Cardiovasc Qual Outcomes2012516822253367
   PubMed Web of Science ®Google Scholar
• LopezADMEzzatiMJamisonDTMurrayCJGlobal Burden of Disease and Risk Factors: Disease Control Priorities ProjectNew York, NYWorld Bank and Oxford University Press2006
   Google Scholar
• PagidipatiNJGazianoTAEstimating deaths from cardiovascular disease: a review of global methodologies of mortality measurementCirculation2013127674975623401116
   PubMed Web of Science ®Google Scholar
• LimSSVosTFlaxmanADA comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592224226023245609
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease Study 2010 Available from: http://www.thelancet.com/themed/global-burden-of-diseaseAccessed June 20, 2013
   Google Scholar
• HortonRGBD 2010: understanding disease, injury, and riskLancet201238098592053205423245595
   PubMed Web of Science ®Google Scholar
• WaldmanSATerzicACardiovascular health: the global challengeClin Pharmacol Ther201190448348521934716
   PubMed Web of Science ®Google Scholar
• LozanoRNaghaviMLimSSGlobal and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592095212823245604
   PubMed Web of Science ®Google Scholar
• Carrera-BastosPFontesMO’KeefeJHLindebergSCordainLThe Western diet and lifestyle and diseases of civilizationRes Rep Clin Cardiol201121535
   Google Scholar
• United Nations General AssemblyNon-communicable diseases deemed development challenge of ‘Epidemic Proportions’9192011 Available from: http://www.un.org/News/Press/docs/2011/ga11138.doc.htmAccessed June 20, 2013
   Google Scholar
• FusterVKellyBBVedanthanRPromoting global cardiovascular health: moving forwardCirculation2011123151671167821502585
   PubMed Web of Science ®Google Scholar
• KishoreSPVedanthanRFusterVPromoting global cardiovascular health ensuring access to essential cardiovascular medicines in low- and middle-income countriesJ Am Coll Cardiol201157201980198721565635
   PubMed Web of Science ®Google Scholar
• KovacicJCCastellanoJMFusterVCardiovascular defense challenges at the basic, clinical, and population levelsAnn N Y Acad Sci2012125411622548564
   PubMedGoogle Scholar
• SpiegelhalterDUsing speed of ageing and “microlives” to communicate the effects of lifetime habits and environmentBMJ2012345e822323247978
   PubMedGoogle Scholar
• JohnsonJLProchaskaJMRulaEYEnhancing multiple domains of well-being by decreasing multiple health risk behaviors: a randomized clinical trialPopul Health Manag201215527628622352379
   PubMed Web of Science ®Google Scholar
• SenesaelEBorgermansLVan De VijverEDevroeyDEffectiveness of a quality improvement intervention targeting cardiovascular risk factors: are patients responsive to information and encouragement by mail or post?Vasc Health Risk Manag201320139132023426275
   PubMedGoogle Scholar
• GaleNMarshallTBramleyGStarting and staying on preventive medication for cardiovascular diseaseCurr Opin Cardiol201227553354122820103
   PubMed Web of Science ®Google Scholar
• GershBJSliwaKMayosiBMYusufSThe epidemic of cardiovascular disease in the developing world: global implicationsEur Heart J201031664264820176800
   PubMed Web of Science ®Google Scholar
• SmithSCJrCollinsAFerrariROur time: a call to save prevention as preventable death from cardiovascular disease (heart disease and stroke)Circulation2012126232769277522988010
   PubMed Web of Science ®Google Scholar
• LaslettLJAlagonaPJrClarkBAIIIThe worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues. A report from the American College of CardiologyJ Am Coll Cardiol201260Suppl 25S1S4923257320
   PubMed Web of Science ®Google Scholar
• CelermajerDSChowCKMarijonEAnsteyNMWooKSCardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detectionJ Am Coll Cardiol201260141207121622858388
   PubMedGoogle Scholar
• World Economic Forum and World Health OrganizationFrom burden to ‘best buys’: reducing the economic impact of non-communicable disease in low- and middle-income countries. Executive SummaryGeneva92011 Available from: http://www.who.int/nmh/publications/best_buys_summary/en/index.htmlAccessed June 20, 2013
   Google Scholar
• NieuwlaatRSchwalmJDKhatibRYusufSWhy are we failing to implement effective therapies in cardiovascular disease?Eur Heart J201334171262126923376448
   PubMed Web of Science ®Google Scholar
• CallahanDObesity: chasing an elusive epidemicHastings Center Report20134313440 Available from: http://www.thehastingscenter.org/Publications/HCR/Detail.aspx?id=6184Accessed June 11, 201323254867
   PubMed Web of Science ®Google Scholar
• CasazzaKFontaineKRAstrupAMyths, presumptions, and facts about obesityN Engl J Med20133685456544
   Web of Science ®Google Scholar
• KheraAVPatelPJReillyMPRaderDJThe addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionalityJ Am Coll Cardiol Prepublication online before print87201310.1016/j.jacc.2013.07.025
   Google Scholar